EGFR-TKI有效治疗晚期非小细胞肺癌患者后疗效判定之思考  

Efficacy evaluation of EGFR-TKI therapy in advanced NSCLC patients

作　　者：关秋红[1] 夏莹[2] 赵艳伟[2] 张力[2] 肖毅[2] 

机构地区：[1]北京中医药大学东直门医院,北京100700 [2]中国医学科学院北京协和医院,北京100005

出　　处：《中国新药杂志》2013年第7期822-825,共4页Chinese Journal of New Drugs

摘　　要：1例晚期非小细胞肺癌(non small-cell lung cancer,NSCLC)患者使用表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)治疗有效后,其胸部影像学出现点片影、胸水时,感染症状不明显,所有症状与原发病进展的症状很相似。本研究客观评价了符合实体肿瘤的RECIST标准的疾病进展(progressive disease,PD),并继续应用EGFR-TKI,同时抗感染治疗使患者获益,从而提出使用EGFR-TKI治疗晚期NSCLC患者有效后疗效判定之思考:如果难以判定,应继续服用EG-FR-TKI,同时进行其他治疗。这类情况以感染原因最为多见,故常需要抗感染治疗。如果停止EGFR-TKI治疗,患者才能最大限度获益。由此提示临床上遇到类似病例时需谨慎评定。One patient with advanced non-small cell lung cancer （NSCLC） received EGFR-TKI therapy. When the effectiveness appeared, thoracic computerized tomography suggested the existence of patching shadow and hydrothorax, but infective symptoms were not significant. All symptoms indicated that the primary disease had de- veloped. Objective responses were considered to conclude a progressive disease according to the Response Evalua- tion Criteria in Solid Tumors （RECIST）. Thereafter the EGFR-TKI therapy continued along with anti-infective ther- apies, which was eventually beneficial. Through analyzing this case, we discussed how the effectiveness is evalua- ted in patients with advanced NSCLC under EGFR-TKI therapy.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 非小细胞肺癌 盐酸埃克替尼 疗效判定 

分 类 号：R979.1[医药卫生—药品]